ערך בספרים למניה: Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals (FENC) management demonstrates high competence in maintaining margins and ensuring transparent control over Pedmark sales. Current revenue growth is driven by the sale of this hearing protection agent for children, with the indicator standing at 1.20. The price action reflects the dynamics of a business that is also developing partnerships with specialized clinics to expand access to therapy for pediatric patients undergoing chemotherapy.

Stable cash flow from the sale of the Inertia drug strengthens the asset base of Fennec Pharmaceuticals (FENC), creating a reliable foundation for capitalization. By analyzing the net asset value per share, an investor can see the residual value of the business minus liabilities, which allows for an assessment of the actual material security of each security and minimizes risks when selecting undervalued assets.